Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Inclusion criteria

• Understand and voluntarily sign the informed consent form;
• 18-70 years of age (inclusive);
• Previously untreated CD19-positive large B-cell lymphoma;
• Anticipated survival ≥12 weeks;
• Adequate bone marrow reserve prior to apheresis
• Appropriate organ function:
• Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma;

• Negative blood/urine pregnancy test in women of childbearing age.

Exclusion criteria

• History of allergy to any of the components of the cell product;
• History of stem cell transplantation;
• History of organ transplantation;
• Presence of active infections;
• Current or history of central nervous system disorders;
• Previous treatment with other modified T-cell therapy;
• Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies;
• Malignancies other than those indicated for this trial;
• History of any prior systemic immune checkpoint therapy;
• History of short-acting cell growth factors or haematopoietic agonists/stimulants ;
• History of a live vaccine within 3 months prior to screening;.